3.35

6.01% 0.19

After Hours: 3.32 -0.03 -0.90%

Rocket Pharmaceuticals Inc (RCKT)

Overview News Price History Option Chain Financials Discussions Forecast Stock Split

Rocket Pharmaceuticals Inc stock is traded at $3.35, with a volume of 11.28M. It is up +6.01% in the last 24 hours and up +9.12% over the past month. Rocket Pharmaceuticals Inc is a late-stage biopharmaceutical company. It is focused on the development of gene therapies for rare and devastating pediatric diseases. The pipeline products of the company include RP-A501 for Danaon Disease, RP-L102 for Fanconi Anemia, RP-L201 for Leukocyte Adhesion, RP-L301 for Pyruvate Kinase Deficiency, and RP-L401 for Infantile Malignant Osteopetrosis. It has one reportable segment related to R&D and commercial readiness of its gene therapies.

Previous Close:

$3.16

Open:

$3.28

24h Volume:

11.28M

Relative Volume:

3.49

Market Cap:

$365.80M

Revenue:

Net Income/Loss:

$-209.38M

P/E Ratio:

-1.785

EPS:

-1.8768

Net Cash Flow:

$-179.81M

1W Performance:

+25.94%

1M Performance:

+9.12%

6M Performance:

+3.72%

1Y Performance:

+18.37%

1-Day Range:

$3.19

$3.38

1-Week Range:

$2.66

$3.38

52-Week Range:

$2.40

$5.45

Rocket Pharmaceuticals Inc Stock (RCKT) Company Profile

Name

Rocket Pharmaceuticals Inc

Sector

Healthcare (1104)

Industry

Biotechnology (617)

Phone

646-440-9100

Address

350 FIFTH AVENUE, NEW YORK, NY

Employee

202

Twitter

@rocketpharma

Next Earnings Date

2026-08-06

Latest SEC Filings

RCKT's Discussions on Twitter

Compare RCKT vs VRTX, REGN, ARGX, ALNY, RVMD

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
RCKT Rocket Pharmaceuticals Inc	3.35	345.05M	0	-209.38M	-179.81M	-1.8768
VRTX Vertex Pharmaceuticals Inc	451.63	116.49B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	609.94	63.73B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	877.72	55.49B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	278.09	37.75B	4.29B	577.22M	641.34M	4.2086
RVMD Revolution Medicines Inc	162.99	33.54B	742.00K	-1.37B	-1.07B	-7.0731

Rocket Pharmaceuticals Inc Stock (RCKT) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Nov-18-25	Downgrade	JP Morgan	Neutral → Underweight
Aug-20-25	Upgrade	BofA Securities	Neutral → Buy
Jul-25-25	Downgrade	BofA Securities	Buy → Neutral
May-30-25	Downgrade	Evercore ISI	Outperform → In-line
May-28-25	Downgrade	Goldman	Neutral → Sell
May-28-25	Downgrade	JP Morgan	Overweight → Neutral
May-28-25	Downgrade	Jefferies	Buy → Hold
May-28-25	Downgrade	Leerink Partners	Outperform → Market Perform
May-28-25	Downgrade	Morgan Stanley	Overweight → Equal-Weight
May-27-25	Downgrade	Needham	Buy → Hold
May-27-25	Downgrade	TD Cowen	Buy → Hold
Mar-12-25	Initiated	BMO Capital Markets	Outperform
Dec-30-24	Initiated	Wedbush	Outperform
Dec-18-24	Initiated	Jefferies	Buy
Oct-16-24	Initiated	Scotiabank	Sector Outperform
Apr-02-24	Initiated	Goldman	Neutral
Oct-24-23	Initiated	Cantor Fitzgerald	Overweight
Feb-01-23	Initiated	Morgan Stanley	Overweight
Nov-08-22	Initiated	Canaccord Genuity	Buy
Nov-01-22	Initiated	BTIG Research	Buy
Jul-08-22	Initiated	Raymond James	Outperform
Oct-20-21	Resumed	Cowen	Outperform
Mar-02-21	Initiated	Stifel	Buy
Feb-18-21	Initiated	Needham	Buy
Dec-16-20	Initiated	UBS	Buy
Dec-08-20	Downgrade	Oppenheimer	Outperform → Perform
Jul-02-20	Initiated	JP Morgan	Overweight
Jun-25-20	Resumed	BofA/Merrill	Buy
Jun-01-20	Resumed	Oppenheimer	Outperform
Nov-06-19	Initiated	Chardan Capital Markets	Buy
Sep-26-19	Initiated	Piper Jaffray	Overweight
Apr-23-19	Initiated	Robert W. Baird	Outperform
Mar-15-19	Initiated	BofA/Merrill	Buy
Feb-05-19	Initiated	Oppenheimer	Outperform
Sep-13-18	Initiated	Ladenburg Thalmann	Buy
Jul-10-18	Initiated	William Blair	Outperform

View All

Rocket Pharmaceuticals Inc Stock (RCKT) Latest News

Jun 18, 2026

Rocket Pharma updates cash position after selling priority review voucher - MSN

Jun 18, 2026